source
- Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle diseaseEpicrispr Biotechnologies announced a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and other investors. The c…
- Veteran scientists launch nonprofit Center for Therapeutic Genetics to advance personalized gene therapiesA group of experienced researchers from top institutions has created the nonprofit Center for Therapeutic Genetics (CTG) to develop personalized genetic medicines. CTG will operate from a modest s…